Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Down 5.2% in March

Hookipa Pharma Inc (NASDAQ:HOOK) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 315,900 shares, a decrease of 5.2% from the March 15th total of 333,400 shares. Currently, 0.5% of the company’s shares are short sold. Based on an average trading volume of 562,100 shares, the days-to-cover ratio is presently 0.6 days.

Institutional Investors Weigh In On Hookipa Pharma

Several hedge funds have recently made changes to their positions in HOOK. Bank of America Corp DE grew its holdings in Hookipa Pharma by 1.2% in the first quarter. Bank of America Corp DE now owns 429,535 shares of the company’s stock worth $316,000 after purchasing an additional 5,199 shares during the period. XTX Topco Ltd bought a new stake in shares of Hookipa Pharma in the 2nd quarter worth approximately $298,000. Goldman Sachs Group Inc. grew its stake in shares of Hookipa Pharma by 117.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 87,217 shares of the company’s stock worth $199,000 after buying an additional 47,168 shares during the last quarter. Renaissance Technologies LLC increased its position in Hookipa Pharma by 50.2% during the 3rd quarter. Renaissance Technologies LLC now owns 142,200 shares of the company’s stock valued at $191,000 after buying an additional 47,500 shares in the last quarter. Finally, State Street Corp increased its position in Hookipa Pharma by 18.5% during the 2nd quarter. State Street Corp now owns 169,174 shares of the company’s stock valued at $149,000 after buying an additional 26,367 shares in the last quarter. 63.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

HOOK has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $6.50 target price on shares of Hookipa Pharma in a research note on Monday, March 25th. Royal Bank of Canada reissued an “outperform” rating and issued a $5.00 price target on shares of Hookipa Pharma in a report on Monday, March 25th.

Hookipa Pharma Stock Performance

Shares of HOOK stock opened at $0.76 on Tuesday. Hookipa Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $2.05. The firm has a market cap of $75.20 million, a P/E ratio of -0.86 and a beta of 1.02. The business’s 50 day moving average price is $0.73 and its 200-day moving average price is $0.64.

Hookipa Pharma (NASDAQ:HOOK) last announced its quarterly earnings results on Friday, March 22nd. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The company had revenue of $7.41 million during the quarter, compared to analyst estimates of $3.60 million. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%. As a group, equities analysts predict that Hookipa Pharma will post -0.51 EPS for the current year.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.